Moderna (MRNA) Reports In-Line Q1 EPS

Moderna (NASDAQ: MRNA) reported Q1 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $17.09 million.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen